MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.
Giulio Draetta was recently named chief strategy officer at Orionis Biosciences, a privately held, clinical stage life sciences company focused on discovery, design, and development of precision medicines for cancer and immune system-related disorders. Orionis is based in Boston and Ghent, Belgium.
